- Home
- SPAI vs ACRV Comparison
SPAI vs ACRV Comparison
Compare SPAI & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPAI
- ACRV
- Stock Information
- Founded
- SPAI 2021
- ACRV 2018
- Country
- SPAI United States
- ACRV United States
- Employees
- SPAI N/A
- ACRV N/A
- Industry
- SPAI Industrial Specialties
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- SPAI Health Care
- ACRV Health Care
- Exchange
- SPAI Nasdaq
- ACRV Nasdaq
- Market Cap
- SPAI 38.5M
- ACRV 40.4M
- IPO Year
- SPAI 2024
- ACRV 2022
- Fundamental
- Price
- SPAI $3.52
- ACRV $1.34
- Analyst Decision
- SPAI
- ACRV Buy
- Analyst Count
- SPAI 0
- ACRV 7
- Target Price
- SPAI N/A
- ACRV $17.60
- AVG Volume (30 Days)
- SPAI 38.6K
- ACRV 379.9K
- Earning Date
- SPAI 08-15-2025
- ACRV 08-12-2025
- Dividend Yield
- SPAI N/A
- ACRV N/A
- EPS Growth
- SPAI N/A
- ACRV N/A
- EPS
- SPAI N/A
- ACRV N/A
- Revenue
- SPAI $2,046,327.00
- ACRV N/A
- Revenue This Year
- SPAI N/A
- ACRV N/A
- Revenue Next Year
- SPAI N/A
- ACRV N/A
- P/E Ratio
- SPAI N/A
- ACRV N/A
- Revenue Growth
- SPAI 140.22
- ACRV N/A
- 52 Week Low
- SPAI $1.47
- ACRV $1.05
- 52 Week High
- SPAI $6.50
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- SPAI N/A
- ACRV 55.88
- Support Level
- SPAI N/A
- ACRV $1.15
- Resistance Level
- SPAI N/A
- ACRV $1.38
- Average True Range (ATR)
- SPAI 0.00
- ACRV 0.09
- MACD
- SPAI 0.00
- ACRV 0.02
- Stochastic Oscillator
- SPAI 0.00
- ACRV 83.33
About SPAI Safe Pro Group Inc. Common Stock
Safe Pro Group Inc operates to acquire security and protection products. Its emphasis is on the development of a cloud-based ecosystem for analyzing drone imagery and data utilizing proprietary artificial intelligence (AI), machine learning, deep learning, and applied computer vision software for hyper-scalable processing, analysis, and reporting. The company operated in three reportable business segments which consisted of: the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. Key revenue is generated from Airborne Response.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.